My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 232

    1.

    Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group.

    Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S, Inada M, Maeda Y, Shirai Y, Fukuzaki T, Kaji I, Ishikawa H, Matsuda Y, Nishikawa M, Seki K, Matsuzawa Y.

    Ann Intern Med. 1998 Jul 15;129(2):94-9.PMID: 9669992 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients.

    Tanaka H, Tsukuma H, Kasahara A, Hayashi N, Yoshihara H, Masuzawa M, Kanda T, Kashiwagi T, Inoue A, Kato M, Oshima A, Kinoshita Y, Kamada T.

    Int J Cancer. 2000 Sep 1;87(5):741-9.PMID: 10925370 [PubMed - indexed for MEDLINE]Related articles

    3.

    Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

    Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G, Omata M.

    Ann Intern Med. 1999 Aug 3;131(3):174-81.PMID: 10428733 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.

    Chen TM, Huang PT, Tsai MH, Lin LF, Liu CC, Ho KS, Siauw CP, Chao PL, Tung JN.

    J Gastroenterol Hepatol. 2007 May;22(5):669-75.PMID: 17444854 [PubMed - indexed for MEDLINE]Related articles

    5.

    Long-term responders without eradication of hepatitis C virus after interferon therapy: characterization of clinical profiles and incidence of hepatocellular carcinoma.

    Yabuuchi I, Imai Y, Kawata S, Tamura S, Noda S, Inada M, Maeda Y, Shirai Y, Fukuzaki T, Kaji I, Ishikawa H, Matsuda Y, Nishikawa M, Seki K, Matsuzawa Y.

    Liver. 2000 Jul;20(4):290-5.PMID: 10959807 [PubMed - indexed for MEDLINE]Related articles

    6.

    Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group.

    Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, Iijima A, Urushihara A, Kiyosawa K, Okuda M, Hino K, Okita K.

    Hepatology. 1998 May;27(5):1394-402.PMID: 9581697 [PubMed - indexed for MEDLINE]Related articles

    7.

    Incidence of hepatocellular carcinoma in chronic hepatitis C after interferon therapy.

    Hayashi K, Kumada T, Nakano S, Takeda I, Kiriyama S, Sone Y, Toyoda H, Shimizu H, Honda T.

    Hepatogastroenterology. 2002 Mar-Apr;49(44):508-12.PMID: 11995484 [PubMed - indexed for MEDLINE]Related articles

    8.

    Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy.

    Makiyama A, Itoh Y, Kasahara A, Imai Y, Kawata S, Yoshioka K, Tsubouchi H, Kiyosawa K, Kakumu S, Okita K, Hayashi N, Okanoue T.

    Cancer. 2004 Oct 1;101(7):1616-22.PMID: 15378504 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Effect of the dose and duration of interferon-alpha therapy on the incidence of hepatocellular carcinoma in noncirrhotic patients with a nonsustained response to interferon for chronic hepatitis C.

    Toyoda H, Kumada T, Nakano S, Takeda I, Sugiyama K, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Hayashi K, Honda T.

    Oncology. 2001;61(2):134-42.PMID: 11528252 [PubMed - indexed for MEDLINE]Related articles

    10.

    Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival.

    Shiratori Y, Ito Y, Yokosuka O, Imazeki F, Nakata R, Tanaka N, Arakawa Y, Hashimoto E, Hirota K, Yoshida H, Ohashi Y, Omata M; Tokyo-Chiba Hepatitis Research Group.

    Ann Intern Med. 2005 Jan 18;142(2):105-14.PMID: 15657158 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.

    Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, Manns MP, Hansen BE, Schalm SW, Janssen HL.

    Ann Intern Med. 2007 Nov 20;147(10):677-84.PMID: 18025443 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Natural course of asymptomatic hepatitis C virus-infected patients and hepatocellular carcinoma after interferon therapy.

    Okanoue T, Minami M, Makiyama A, Sumida Y, Yasui K, Itoh Y.

    Clin Gastroenterol Hepatol. 2005 Oct;3(10 Suppl 2):S89-91.PMID: 16234069 [PubMed - indexed for MEDLINE]Related articles

    13.

    Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.

    Shindo M, Ken A, Okuno T.

    Cancer. 1999 May 1;85(9):1943-50.PMID: 10223234 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Clinical characteristics of patients with chronic hepatitis C showing biochemical remission, without hepatitis C virus eradication, as a result of interferon therapy. The Osaka Liver Disease Study Group.

    Kasahara A, Hayashi N, Mochizuki K, Hiramatsu N, Sasaki Y, Kakumu S, Kiyosawa K, Okita K.

    J Viral Hepat. 2000 Sep;7(5):343-51.PMID: 10971822 [PubMed - indexed for MEDLINE]Related articles

    15.

    Effectiveness of interferon therapy for reducing the incidence of hepatocellular carcinoma among patients with type C chronic hepatitis.

    Inoue A, Tsukuma H, Oshima A, Yabuuchi T, Nakao M, Matsunaga T, Kojima J, Tanaka S.

    J Epidemiol. 2000 Jul;10(4):234-40.PMID: 10959605 [PubMed - indexed for MEDLINE]Related articles

    16.

    Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.

    Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling MH, Albrecht J.

    N Engl J Med. 1998 Nov 19;339(21):1493-9.PMID: 9819447 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Effects of interferon alpha 2a on incidence of hepatocellular carcinoma in chronic active hepatitis without cirrhosis. Hepatitis Treatment Study Group.

    Sata M, Ide T, Akiyoshi F, Fukuizumi K, Noguchi S, Shirachi M, Sasaki M, Uchimura Y, Suzuki H, Tanikawa K.

    Kurume Med J. 1997;44(3):171-7.PMID: 9339647 [PubMed - indexed for MEDLINE]Related articles

    18.

    Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon.

    Veldt BJ, Hansen BE, Ikeda K, Verhey E, Suzuki H, Schalm SW.

    Scand J Gastroenterol. 2006 Sep;41(9):1087-94.PMID: 16938723 [PubMed - indexed for MEDLINE]Related articles

    19.

    Interferon therapy for hepatocellular carcinoma patients with low HCV-RNA levels.

    Miyaguchi S, Watanabe T, Takahashi H, Nakamura M, Saito H, Ishii H.

    Hepatogastroenterology. 2002 May-Jun;49(45):724-9.PMID: 12063979 [PubMed - indexed for MEDLINE]Related articles

    20.

    Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group.

    Okanoue T, Itoh Y, Minami M, Sakamoto S, Yasui K, Sakamoto M, Nishioji K, Murakami Y, Kashima K.

    J Hepatol. 1999 Apr;30(4):653-9.PMID: 10207807 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity